CXCR4 and leukemia: Monomethyl auristatin E conjugated with the CXCR4‐targeted protein nanoparticles could be utilized to kill CXCR4+ AML cells and to reduce leukaemia burden in mice without the severe toxicity of classical AML therapeutic drugs.83